Omnicell, Inc. (OMCL)
NMS · Health Information Services
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Peers in Health Information Services
All in industry →Veeva Systems Inc.
BrightSpring Health Services, Inc.
Tempus AI, Inc.
HealthEquity, Inc.
Waystar Holding Corp.
Doximity, Inc.
10x Genomics, Inc.
Privia Health Group, Inc.
Hinge Health, Inc.
HeartFlow, Inc.
Recent press releases
April 2026
OMNICELL, INC. — PRE 14A Filing
# 🧾 What This Document Is This is a **preliminary proxy statement (PRE 14A)** for Omnicell's 2026 Annual Meeting. Think of it as a detailed "voting guide" and information packet sent to shareholders before the meeting. It explains what the company wants shareholders to vote on and provides backgrou
SEC filings
All filings →Insider trades
All insider trades →Omnicell, Inc. has no reported insider trades in the last 90 days.